Our top pick for
Medpace Holdings, Inc is a diagnostics & research business based in the US. Medpace shares (MEDP) are listed on the NASDAQ and all prices are listed in US Dollars. Medpace employs 3,400 staff and has a trailing 12-month revenue of around USD$896.1 million.
|Latest market close||USD$140.12|
|52-week range||USD$58.72 - USD$150.57|
|50-day moving average||USD$131.7782|
|200-day moving average||USD$117.8123|
|Wall St. target price||USD$127.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$3.289|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-1.16%|
|1 month (2020-12-15)||-2.78%|
|3 months (2020-10-15)||10.89%|
|6 months (2020-07-15)||33.37%|
|1 year (2020-01-15)||57.21%|
|2 years (2019-01-15)||131.72%|
|3 years (2018-01-12)||277.68%|
|5 years (2016-01-11)||N/A|
Valuing Medpace stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medpace's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Medpace's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 42x. In other words, Medpace shares trade at around 42x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Medpace's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.97. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Medpace's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Medpace's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$167.5 million.
The EBITDA is a measure of a Medpace's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$896.1 million|
|Operating margin TTM||16.54%|
|Gross profit TTM||USD$540 million|
|Return on assets TTM||7.82%|
|Return on equity TTM||16.76%|
|Market capitalisation||USD$5 billion|
TTM: trailing 12 months
There are currently 996,708 Medpace shares held short by investors – that's known as Medpace's "short interest". This figure is 32.1% up from 754,369 last month.
There are a few different ways that this level of interest in shorting Medpace shares can be evaluated.
Medpace's "short interest ratio" (SIR) is the quantity of Medpace shares currently shorted divided by the average quantity of Medpace shares traded daily (recently around 220510.61946903). Medpace's SIR currently stands at 4.52. In other words for every 100,000 Medpace shares traded daily on the market, roughly 4520 shares are currently held short.
However Medpace's short interest can also be evaluated against the total number of Medpace shares, or, against the total number of tradable Medpace shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Medpace's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Medpace shares in existence, roughly 30 shares are currently held short) or 0.0528% of the tradable shares (for every 100,000 tradable Medpace shares, roughly 53 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Medpace.
Find out more about how you can short Medpace stock.
We're not expecting Medpace to pay a dividend over the next 12 months.
Over the last 12 months, Medpace's shares have ranged in value from as little as $58.72 up to $150.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Medpace's is 1.3456. This would suggest that Medpace's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.